Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.54 |
| ▸ | SLC5A1 | P13866 | 8/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1634306 | 0.86 | SLC5A2 (0.56) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1632114 | 0.84 | SLC5A2 (0.52) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL24923615 | 0.82 | SLC5A2 (0.63) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL29201212 | 0.82 | SLC5A2 (0.63) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1551581 | 0.82 | SLC5A2 (0.63) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL23453212 | 0.82 | SLC5A2 (0.63) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL30783573 | 0.82 | SLC5A2 (0.63) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL3799163 | 0.82 | SLC5A2 (0.63) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL30437943 | 0.82 | SLC5A2 (0.63) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19867558 | 0.82 | SLC5A2 (0.63) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375213-B2 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example dapagliflozin | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| US-20040138439-A1 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example 1-C-(substituted diphenylmethane-3-yl)- beta -D-glucopyranose | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138439-A1 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example 1-C-(substituted diphenylmethane-3-yl)- beta -D-glucopyranose | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.